Wells Fargo Maintains Overweight on Acelyrin, Raises Price Target to $15

Benzinga · 10/16 15:42
Wells Fargo analyst Derek Archila maintains Acelyrin (NASDAQ:SLRN) with a Overweight and raises the price target from $13 to $15.